Danen Capital
旦恩资本
elsewhere's corpus does not cover Danen Capital as a subject in its own right. The only mentions of the fund in the retrieved material are as a co-investor alongside Linear Capital in two synthetic-biology deals: SynMetabio's Pre-A round in 2024 and SynBioRay's angel round in 2023 . No founding date, team, strategy, or fund size is provided in these background references.
AI-generated — may contain errors, please verify.
Danen CapitalFund
旦恩资本
渲染中…
Mentioned in 3 articles
Coverage
AI Tech Drives Down Enzymatic DNA Synthesis Costs, Enzymo Technology Raises Tens of Millions in Angel Round Led by Linear Capital
Achieve de novo DNA synthesis at one-tenth the cost of chemical methods.
Linear Capital's angel-round lead investment project, *SynMetabio*, has raised tens of millions of RMB in a Pre-A round, with existing investor Linear Capital continuing to double down as a follow-on investor.
The cost of bio-based leather manufacturing has dropped sharply, and a commercial inflection point could arrive next year, with tens of millions of yuan in revenue.
Synthetic biology startup **SynBioRay** (贻如生物) has raised tens of millions of RMB in funding, with **Linear Capital** leading the angel round.
Using synthetic biotechnology to cultivate 100% bio-based leather.
